US-based Carematix has unveiled its Cellular Weight Scale, a new remote patient monitoring (RPM) weight scale that tracks and shares patient weight measurements with healthcare professionals in real time.
The scale is intended to help monitor weight fluctuations in patients with chronic conditions such as heart disease, diabetes, and obesity and assist healthcare professionals in developing personalised patient care plans.
Carematix claims that sensors in the scale also measure weight asymmetry to provide healthcare professionals with data on how weight is being distributed throughout the body.
Weight-bearing asymmetry (WBA), in which someone puts more weight on one leg than the other while standing, is commonly observed in individuals who have experienced a stroke or injury, or undergone orthopaedic procedures such as anterior cruciate ligament (ACL) reconstruction.
According to Carematix, its scale’s WBA functionality can indicate underlying musculoskeletal issues, including scoliosis, hip dysplasia, and limb length discrepancies.
Past research indicates that the ability to adequately intervene and correct WBA in patients, including stroke victims, results in improved gait restoration and associated recovery outcomes in the long term.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCarematix CEO Sukhwant Khanuja said its scale, the latest device in the company’s wellness device portfolio, which also includes a glucometer and blood pressure monitor, was a “milestone” in its mission to enhance RPM.
“By delivering accurate, real-time weight data, this device enables both patients and healthcare providers to make better-informed decisions, ultimately improving health outcomes and patient quality of life,” commented Khanuja.
GlobalData’s Market Size & Growth database indicates that the overall patient monitoring market was valued at around $18bn in 2023. Growing at a CAGR of 2.6%, it is forecast to reach a valuation of almost $24bn by 2033.
As per GlobalData analysis, 14 RPM devices are in active stages of development globally. Key players in the RPM space include Boston Scientific and Bharat Electronics.